● Recruiting

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Condition: Colorectal Adenocarcinoma · Sponsor: Akeso

PhasePhase 3

Planned participants560

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Xufang Yu, MD · +86(0760)89873999 · clincialtrails@akesobio.com

Always discuss trial participation with your own doctor first.

Locations (2)

The Sixth Hospital,Sun Yat-sen University	Guanzhou, Guangdong, China	Recruiting
Sun Yat-sen University Cancer Center	Guanzhou, Guangdong, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06951503